ENTITY

Shield Therapeutics (STX LN)

47
Analysis
Health Care • United Kingdom
Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on pharmaceuticals for unmet medical needs. Its primary product, Accrufer/Feraccru (ferric maltol), is an oral therapy for iron deficiency with or without anemia. The company was founded in 2008 and is headquartered in Gateshead, United Kingdom.
more
•04 Nov 2024 09:33•Issuer-paid

The Hardman & Co Monthly: November 2024

Feature article: “ROOM” (Running Out of Money) risk, How managing liquidity risk can sustain corporate value and maintain shareholder confidence

Logo
388 Views
Share
•02 Oct 2024 06:30•Issuer-paid

Hardman & Co Monthly: October 2024

This paper considers the impact of increases in rates for those taxes that affect investors, and the withdrawal of tax concessions and reliefs.

Logo
295 Views
Share
•02 Sep 2024 00:00•Issuer-paid

Hardman & Co Monthly: September 2024

Feature article: The Tiktok generation are becoming “renegade” investors - How Gen Z’s investing habits differ from past generations As the...

Logo
130 Views
Share
•03 Aug 2024 04:48•Issuer-paid

Hardman & Co Monthly: August 2024

The recent change in the UK government may bring some relief, with potential relaxations in planning approvals for new onshore wind and solar plants.

Logo
615 Views
Share
•04 Jul 2024 05:52•Issuer-paid

Hardman & Co Monthly: July 2024

In 2023, and for the second year running, the Hardman & Co sector index declined, by 3.7%, underperforming both the FTSE 100 and the FTSE All-Share...

Logo
386 Views
Share
x